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Erwinia asparaginase is an important component in the treatment ofpediatric acute lymphoblastic leukemia. A large variability in serumconcentrations has been observed after intravenous Erwinia
asparaginase. Currently, Dutch Childhood Oncology Group protocols
dose alterations are based on trough concentrations to ensure adequate
asparaginase activity (≥100 IU/L). The aim of this study was to describe
the population pharmacokinetics of intravenous Erwinia asparaginase to
quantify and gather insight into inter-individual and inter-occasion vari-
ability. The starting dose was evaluated on the basis of the derived pop-
ulation pharmacokinetic parameters. In a multicenter prospective obser-
vational study, a total of 714 blood samples were collected from 51 chil-
dren (age 1-17 years) with acute lymphoblastic leukemia. The starting
dose was 20,000 IU/m2 three times a week and adjusted according to
trough levels from week three onwards. A population pharmacokinetic
model was developed using NONMEM®. A 2-compartment linear model
with allometric scaling best described the data. Inter-individual and inter-
occasion variability of clearance were 33% and 13%, respectively.
Clearance in the first month of treatment was 14% higher (P<0.01).
Monte Carlo simulations with our pharmacokinetic model demonstrated
that patients with a low weight might require higher doses to achieve
similar concentrations compared to patients with high weight. The cur-
rent starting dose of 20,000 IU/m2 might result in inadequate concentra-
tions, especially for smaller, lower weight patients, hence dose adjust-
ments based on individual clearance are recommended.  The protocols
were approved by the institutional review boards. (Registered at NTR
3379 Dutch Trial Register; www.trialregister.nl).
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Introduction
Asparaginase is an enzyme that catalyzes the hydrolysis
of asparagine to aspartic acid and ammonia. Leukemic
cells rely on exogenous supplies of asparagine for their
protein synthesis. Hence the depletion of asparagine
results in cell death.1 Asparaginase has become an impor-
tant component in the treatment of pediatric acute lym-
phoblastic leukemia (ALL), and therefore every effort
should be made to expose the patient to the protocol-pre-
scribed cumulative dose.2-6 Erwinia asparaginase is derived
from Erwinia chrysanthemi, whereas the other forms of
asparaginase [native Escherichia coli (E. coli) and polyethyl-
ene glycol (PEG)-asparaginase] are derived from E. coli.
Currently the E. coli derivatives are the first choice in treat-
ment naïve patients, and the use of Erwinia asparaginase
is indicated in patients who develop hypersensitivity to
the E. coli-derived asparaginase or in the case of silent inac-
tivation of E. coli asparaginase.4,7,8
Little is known about the pharmacokinetics (PK) of
Erwinia asparaginase, especially after intravenous admin-
istration. Currently, in the Dutch Childhood Oncology
Group (DCOG) ALL-11 protocol (and the preceding ALL-
10), the interval and/or dose alterations of Erwinia
asparaginase are based on therapeutic drug monitoring
(TDM), with the aim of keeping the trough asparaginase
activity above the 100 IU/L threshold, which leads to
complete asparagine depletion.7,9-13 A concentration of 100
IU/L is considered safe concerning asparagine depletion;
however, complete depletion has been observed at lower
concentrations.14-16 Currently, the consensus for the target
threshold is 100 IU/L.17 No evidence-based guidelines for
increasing or decreasing the dose are available and dose-
adaptations are based on empirical knowledge. 
The PK data of different asparaginase forms are not
transferrable. Intramuscular native E. coli asparaginase has
an elimination half-life of 1.3 days,18 and intravenous
recombinant and native E. coli asparaginase 17.3-19.0
hours (h),19,20 and follow linear elimination, whereas E. coli
PEG-asparaginase has time-dependent pharmacokinetics
and a half-life with an observed range of 2.4-11.8
days.9,18,21,22 Erwinia asparaginase has the shortest half-life
with means of 12.6-22.1 h after intramuscular administra-
tion,7,9,23,24 and 6.4-7.6 h after intravenous administra-
tion.23,25
The aim of the present study was to describe the popu-
lation PK of intravenously administered Erwinia asparagi-
nase in pediatric ALL patients, to quantify the random
parameters inter-individual (IIV), inter-occasion (IOV) and
residual variability, and to determine the association
between patients’ characteristics and the PK parameters.
Quantification of random parameters is important for
proper TDM, as IIV can be compensated by TDM, where-
as IOV cannot. In addition, the current starting dose was
evaluated considering a trough concentration above 100
IU/L. 
Methods
Patients’ characteristics and treatment
The study was designed as a prospective multicenter study in 7
pediatric oncology centers in the Netherlands. Children aged 1-18
years with acute lymphoblastic leukemia (ALL) were eligible for
the study when treated according to the DCOG ALL-10 (Nov 1,
2004-April 1, 2012) or ALL-11 (since April 1, 2012 and ongoing)
protocols with Erwinia asparaginase (Erwinase®; EUSA Pharma,
Europe) after the development of an allergy to E. coli-derived
asparaginase or silent inactivation of E. coli-derived asparaginase.
The starting dose of Erwinia asparaginase was 20,000 IU/m2 intra-
venously (i.v.) over 1 h thrice weekly (Mon/Wed/Fri). The dose
was fixed for the first two weeks. Subsequently, if the 72 h con-
centration was more than 100 IU/L, the dose interval was adjusted
to twice weekly. Additionally in ALL-11, the dose was increased
based on clinical expertise if the 72 h concentration was less than
100 IU/L. When this was not sufficient, the dose interval was set
to every other day. The TDM samples were collected between
May 1, 2009 and February 5, 2015. These are trough samples prior
to their next dose, predominantly 48 or 72 h after the last Erwinia
asparaginase administration. For the purpose of this study, addi-
tional peak concentrations were collected between 1 and 4 h in a
subset of patients. Erwinia asparaginase activity concentrations in
serum were analyzed as previously described by us, with a lower
limit of quantification (LLoQ) of less than 5 IU/L.26 The protocols
were approved by a central Institutional Review Board.
Pharmacokinetic analysis
A detailed description of the pharmacokinetic analysis methods
is provided in the Online Supplementary Appendix. Time profiles of
log transformed Erwinia asparaginase concentrations were ana-
lyzed using the non-linear effects modeling approach implement-
ed in non-linear mixed effects modeling (NONMEM). The data
were initially fitted to a 1-compartment linear model without an
absorption compartment. Subsequently more complex models
were evaluated; improvement of the fit was evaluated by the pre-
cision of the estimated PK parameters, change in the objective
function values (OFV), goodness-of-fit plots (GOF), and visual pre-
dictive checks (VPC). A 3.84-point decrease in OFV for one degree
of freedom was considered a significant improvement (P<0.05). 
The data were obtained in a pediatric population, hence PK
parameters were allometrically scaled to adequately describe the
parameters across a wide range of body weights. For allometric
scaling, standard fixed exponent values of 0.75 for the flow
dependent physiological process parameters and 1 for volume-
related parameters were used.27-29 Inter-patient and inter-occasion
variability in clearances and volumes of distribution were charac-
terized with exponential models. An additive error model was
used to describe the residual error in plasma concentrations. 
After the finalization of the structural model, covariate models
were built by a stepwise forward inclusion procedure. The covari-
ate with the greatest reduction in OFV was added to the base
model. This was iterated over all the covariates until no statistical-
ly significant decrease in OFV occurred. For the internal validation
of the model, non-parametric bootstrap procedures (n=1000) were
performed and VPCs were obtained. The final model including
covariates was used to perform Monte Carlo simulations (n=5000)
for different doses and patient weight.
Results
Patients and samples
During the study period, 53 patients were switched
from E. coli-derived asparaginase to Erwinia asparaginase
due to allergic reactions or silent inactivation. Data from
51 of these 53 patients were included in the PK analysis.
Two patients were excluded due to Erwinia asparaginase
concentrations below the LLoQ. One of these patients had
anti-Erwinia asparaginase antibodies neutralizing the drug
and prohibiting sufficient exposure, for the other patient
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the reason for unmeasurable concentrations is not known.
Both patients discontinued treatment with Erwinia
asparaginase. A summary of patients’ characteristics is
shown in Table 1. A total of 741 samples were available,
with a median of 11 samples per patient (range 2-43 sam-
ples). Twenty-seven samples (3.6%) were excluded from
the analysis due to: missing sampling data (n=20), no
measurable asparaginase (n=4), or unrealistic high concen-
trations (n=3) due to sampling artefacts. The four unmea-
surable trough concentrations were all from the same
patient; however, this patient did have measurable
Erwinia asparaginase concentrations within 24 h after
administration. 
Samples were collected for two weeks up to 12 months
after the start of Erwinia asparaginase treatment. Samples
were predominantly trough concentrations taken around
48 h (52.2%) and 72 h (36.8%)  after Erwinia asparaginase
administration. Figure 1 shows the combined Erwinia
asparaginase concentrations versus the time after dose for
all patients throughout therapy, demonstrating a large
variability. The concentrations can be stratified for the first
two weeks of treatment (no dose adjustments), and after
two weeks with potential adjustments (TDM) in Erwinia
asparaginase dose frequency (both ALL-10 and ALL-11
protocol) and dose (ALL-11 protocol only). The median
asparaginase trough concentrations two days after admin-
istration (range 42-50 h) for, respectively, the first two
weeks and during TDM, were 166.2 IU/L [interquartile
range (IQR) 103.4-270.1] and 191.0 IU/L (IQR 115.0-
296.5); 75.4% and 82.6% of the patients had asparaginase
trough concentrations of 100 IU/L or more; 90.16% and
91.30% had trough concentrations of 50 IU/L or more.
Three days after administration (65-80 h), the median
trough concentrations for, respectively, the first two
weeks and during TDM, were 48.4 IU/L (IQR 29.9-104.7)
and 83.7 IU/L  (IQR 49.5-98.7); 26.4% and 39.5% of the
patients had trough concentrations of 100 IU/L or more;
50% and 74.3% had trough concentrations of 50 IU/L or
more.
The summary of the number of samples and time points
can be found in Table 2. A total of 311 samples (43.6%)
were collected in the first month of Erwinia asparaginase
treatment. The number of samples during the following
months ranged from 86 (in month 2) to 1 (in month 12).
Especially trough concentrations taken at 72 h frequently
dropped below the desired therapeutic target threshold of
100 IU/L. Eleven patients (21.6%) were switched from
thrice to twice weekly interval after asparaginase 72 h
trough concentrations of more than 100 IU/L during their
treatment. A total of 117 samples (15.5%) were drawn
during a twice-weekly interval.  
Pharmacokinetic model
Both 1- and 2-compartment models were evaluated.
The estimated PK parameters were normalized to a
weight of 70 kg using the ¾ allometric model. The 2-com-
partment model provided a better fit to the data than a 1-
compartment model based on the OFV and the goodness-
of-fit plots. The OFV significantly decreased 127.2 points
from 366.5 to 239.3 (P<0.001). A slight decrease in addi-
tive error was observed from 0.70 IU/L (1-compartment
model) to 0.64 IU/L (2-compartment model). Addition of a
third compartment did not improve the model. A
Michaelis-Menten elimination model did not improve the
model either.  
The estimated IIV on CL was 36%, whereas this param-
eter could not be estimated for distribution of the central
compartment (Vc), intercompartmental clearance (Q) and
distribution of the peripheral compartment (Vp).
Complete removal of the a priori incorporated allometric
scaling from the model, based on body weight (standard-
ized for 70 kg) and fixed exponents, resulted in a worse
model with a 8.3 points increase in OFV and an increase
of the IIV for CL from 33% to 40%. Samples were collect-
ed throughout therapy on different occasions. Addition of
IOV resulted in an improvement of the population model
with an estimated value of 14%. By incorporation of the
IOV, the OFV decreased with 44.9 points, additive error
decreased from 0.64 to 0.57, and the IIV for CL decreased
from 36% to 33%. The shrinkage was 6% for IIV on CL,
32% for IOV on CL and 9% for residual variability. This
was considered the structural model and was used for the
stepwise forward inclusion of covariates. 
All covariates were tested one at a time for improve-
ment of the structural model. The clearance in the first
month was 14% higher in comparison to the subsequent
months with a decrease of 17.0 points in OFV (P<0.001).
Dose as a covariate on CL also improved the model
(P<0.05). However, during TDM, the dose is adjusted
according to the patients’ asparaginase concentrations and
S.D.T. Sassen et al.
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Table 1. Patients’ characteristics.
Patients characteristics 
Total patients, n                                                                        51
Age, y                                                                                             
Median                                                                                       6
Range                                                                                   1.9-17.7
Sex, n, %                                                                                       
Male                                                                                   32 (62.7%)
Female                                                                             19 (37.3%)
Weight, kg                                                                                     
Median                                                                                    24.5
Range                                                                                  11.7-99.0
BSA m2                                                                                           
Median                                                                                    0.92
Range                                                                                  0.53-2.22
y: years; kg: kilograms; BSA: body surface area.
Table 2. Samples for pharmokinetic analysis.
Samples                                                                 N (%)
Total samples                                                                        741
Evaluable                                                                     714 (96.4%)
Not evaluable                                                                27 (3.6%)
Pre-TDM                                                                       225 (31.5%)
During TDM                                                                 489 (68.5%)
Samples per patient                                                               
Median                                                                                   11
Range                                                                                   2-43
Sample time*                                                                           
Within 5 h                                                                       17 (2.4%)
5-40 h                                                                                9 (1.3%)
After 48 h                                                                     373 (52.2%)
After 72 h                                                                     263 (36.8%)
80-120 h                                                                          52 (7.3%)
TDM: therapeutic drug monitoring; h: hours.*Sample time is the time after last
Erwinia asparaginase administration in hours.
therefore indirectly for their clearance, which explains the
correlation between dose and clearance. Similarly, an asso-
ciation between dose interval and clearance was detected.
With dose interval as covariate, the OFV significantly
decreased 6.11 points (P<0.05) and patients with twice
weekly dosing (n=11) were associated with a 24% lower
CL in comparison with patients on thrice weekly dosing
(n=40). Due to TDM, dose and dose interval were not
incorporated in the model. The other covariates [age,
weight, height, BSA, sex, treatment protocol (ALL-10 or
ALL-11) and treatment center] did not result in a signifi-
cant improvement of the base model.
The final model was a 2-compartment model with fixed
exponents allometric scaling, a correction factor for
increased clearance in the first month, and inter-individual
and inter-occasion variability on clearance. The parameter
estimates of the final model were: CL 0.44 L/h/70kg, Vc
(central compartment) 3.2 L/70kg, Q (intercompartmental
clearance) 0.15 L/h/70kg and Vp (peripheral compartment)
2.9 L/70kg. The calculated half-lives (t1/2) for the 2-com-
partment model are T1/2,a 3.5 h and T1/2,b 19.6 h, which
represent respectively the distribution phase and elimina-
tion phase. The inter-individual variability of clearance
was 33%. There was an inter-occasion variability of 13%
based on monthly intervals (Table 3). The basic goodness-
of-fit plots (Figure 2) show good model performance.
Individual predictions versus observation are well distrib-
uted around the unity line. The weighted residuals are
within a good range (2 to -2) and evenly distributed. The
population predictions show a deviation from the unity
line for the lower concentrations where limited samples
were available.
Model validation
The non-parametric bootstrap procedure was per-
formed to test the robustness of the model. A total 998 of
the 1000 runs were successful. The results are shown in
Table 3. The estimates of the final model are in accordance
with the results from the 1000 bootstrap replicates. The
plot of the prediction corrected visual predictive check
(pcVPC) shows the median and 90% interval of the
observed asparaginase concentrations (Figure 3). The
model adequately predicts the time course of the asparag-
inase plasma concentration during the first three time
frames (0-36 h, 36-60 h and 60-84 h). However, an under-
prediction of median concentrations and 5th and 95th per-
centiles was observed in the 84-118 h timeframe. 
Evaluation of the starting dose
To investigate the appropriateness of the starting dose,
Monte Carlo simulations with varying weights and doses
were performed utilizing the developed population PK
model. Based on the simulations, patients with a lower
body weight appeared to require higher weight-normal-
ized starting doses to achieve sufficient Erwinia asparagi-
nase concentrations after 48 h. Patients weighing 100 kg
require 500 IU/kg compared to doses exceeding 1000
IU/kg for patients with a body weight below 20 kg in
order to have Erwinia asparaginase concentrations of 100
IU/L  or more in 75% of the patients at 48 h after admin-
istration (Figures 4 and 5). With the current starting dose
of 20,000 IU/m2, approximately 75% of the patients with
a body weight of more than 50 kg would have concentra-
tions of 100 IU/L or more after 48 h. For patients with a
body weight between 30-50 kg, the suggested starting
dose would be 25,000 IU/m2, and for patients with a body
weight of 10-30 kg doses of 25,000-37,000 IU/m2 to
achieve Erwinia asparaginase concentrations of 100 IU/L
or more after 48 h in at least 75% of the patients after the
first dose. To achieve this in 90% of the patients, starting
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Figure 1. Asparaginase concentration (IU/L) versus time after dose in hours (h) for all patients and all occasions on a semi-log plot. This shows the large inter-patient
variability in plasma concentrations as collected throughout treatment. Triangles (black) show concentrations prior to possible dose adjustments (first 2 weeks) and
circles (blue) show observed concentrations with possible dose adjustments [therapeutic drug monitoring (TDM) after week two]. 
dose for all patients would have to be above 33,000 IU/m2.
The dose in IU/kg was converted to IU/m2 utilizing corre-
sponding BSA to weight for pediatric oncology patients.30
Figures 5 and 6 show required starting dose (in IU/kg and
IU/m2) versus weight to achieve 48 h-trough concentration
of 100 IU/L or more (Figure 5) and of 50 IU/L or more
(Figure 6) in a percentage of patients ranging from 10% to
90%. The simulations with the final PK model are in
accordance with the observations made in the patient
data. Starting doses of 36 patients were evaluable (Erwinia
asparaginase dose of 20,000 IU/m2 and an available 48 h
sample after administration of the first dose). With respect
to weight, 12 of 31 patients (39%) weighing less than 50
kg and and 1 of 5 patients (20%) weighing 50 kg or more
had 48 h trough concentrations below 100 IU/L. Although
these numbers are small, it shows the same trend in
weight-concentration relationship as the Monte Carlo
simulations. 
Discussion
The PK of Erwinia asparaginase was best described with
a 2-compartment model with linear elimination and,
therefore, more similar to native asparaginase than
PEGylated asparaginase which has time-dependent elimi-
nation, probably due to the polyethylene glycol.21 There
appears to be a negative correlation between weight and
weight-normalized clearance, where the patients with a
lower weight require higher weight-normalized doses
based on Monte Carlo simulations with the final PK
model. The same trend was observed in the actual patient
data; however, only a small number of patients had a body
weight of more than 50 kg.  In addition, clearance in the
first month was significantly higher. 
Asparaginase is an important component in the treat-
ment of pediatric ALL, where it contributes 10%-20% to
the total treatment outcome.6,11,12,19,31,32 However, treatment
with asparaginase at suboptimal dose schedules leads to
an inferior outcome.11-13,32 Asparaginase is available in dif-
ferent molecular forms (eg. PEGylated or native). The PK
properties of these different forms are, however, not sim-
ilar, and therefore can not be used interchangeably.9,18,33
Erwinia asparaginase has a shorter half-life in comparison
with the other asparaginase forms; this results in lower
concentrations and exposure when administered at equal
dose schedules and, consequently, worse outcome.11-13
In North-America, intramuscular injection of Erwinia
asparaginase was the only Food and Drug Administration
(FDA)-approved method of administration, but this has
recently been extended with i.v. administration.34 In
Europe, the predominant method of Erwinia asparaginase
administration is i.v. administration. Several PK studies of
intramuscular administration have been published.8,9,23,24
This is important in studying the PK because, in addition
to the asparaginase molecule or pharmaceutical form, the
route of administration may also influence the PK. The PK
of intramuscular-administered Erwinia asparaginase dif-
fers from i.v. administration due to the presence of a rate-
limiting step in the absorption phase.23,24,34 Bypassing the
absorption from the muscle will result in faster elimina-
tion and probably more predictable concentrations, as
variability in absorption rate is eliminated. The calculated
terminal half-life was 19.6 h, which is similar to the termi-
nal half-life of the i.v.-administered native E. coli asparagi-
nase of 19.0 h.22 Previously published studies with i.v.
S.D.T. Sassen et al.
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Figure 2. Goodness-of-fit plots final model. (Upper left) Predicted population concentrations versus observed concentrations of the final model. (Upper right)
Predicted individual concentrations versus observed concentrations of the final model. (Lower left) Individual weighted residuals versus individual predictions,
(lower right) conditional weighted residuals versus time after dose. h: time in hours; IWRES: individual weighted residual predictions. 
Erwinia asparaginase showed a half-life of 6.4 h and 7.5
h.23,25 However, our study uses a 2-compartment model
which has a fast elimination half-life of 3.5 h during the
distribution phase and a slower elimination half-life of
19.6 h for the terminal elimination phase. This presents
itself in a concentration time curve with a steep decline in
the first phase followed by a slower decline in the second;
this can also be observed in Figures 1 and 3.
During TDM, a large variability in Erwinia asparaginase
concentrations was also observed after i.v.-administered
Erwinia asparaginase (Figure 1). Hence the population PK
of Erwinia asparaginase was studied to evaluate the elim-
ination of Erwinia asparaginase from the body in a quan-
titative manner, and to explain and quantify the variability
in order to improve individual dosing to achieve sufficient
asparaginase concentrations prior to their next dose. PK-
based TDM dosing can compensate for IIV, but not for
IOV. In this study, the IIV was 33% and the IOV was 13%,
which is favorable for PK-based dosing. 
The development of the PK model was successful
despite the limited number of peak concentrations. The
parameters were estimated with good precision; the
shrinkage of IIV and the residual error was small. The
bootstrap estimates were also in accordance with the
model estimates. The VPC showed the model predictions
to be in line with the observations, except for the last time
frame (84-118 h), which showed a slight under-prediction
(Figure 3). However, samples in this timeframe were
patients who were switched to twice-weekly Erwinia
asparaginase administration due to high asparaginase con-
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Figure 3. Visual predictive check. Prediction corrected (Pred Corr) visual prediction plot of observed log asparaginase concentrations versus time after last Erwinia
asparaginase dose in hours (h) of the final model. Red solid line  shows the median observed concentrations and the surrounding opaque red area the simulation
based 95% interval for the median. Red dashed lines indicate the observed 5% and 95% percentiles; surrounding opaque blue areas show the simulated 95% con-
fidence intervals for the corresponding predicted percentiles.
Table 3. Population parameter estimates and non-parametric bootstrap. 
Parameter estimates Bootstrap
Estimate RSE (%) 95%CI 95%CI Shrink Median 95%CI 95%CI 
(lower) CI (upper) (%) (lower) (upper)
CL (L/h/70kg) 0.44 11% 0.35 0.53 - 0.42 0.32 0.54
Vc (L/70kg) 3.2 22% 1.8 4.6 - 3.3 2.2 6.9
Q (L/h/70kg) 0.15 44% 0.02 0.28 - 0.13 0.01 0.33
Vp (L/70kg) 2.9 35% 0.9 5.0 - 2.7 0.7 5.3
CL month 1 diff 1.1 3% 1.06 1.22 - 1.12 1.05 1.20
IIV CL (%) 33 20 20 45.2 5.5 30 18 42
IOV (%) 13 18 8 17.2 31.9 11 6 17
Residual error (IU/L) 0.57 6.4% 0.50 0.65 8.5 0.57 0.50 0.63
RSE: residual standard error; CI: confidence interval; CL: population estimate for clearance; Vc: population estimate of apparent volume of distribution in central compartment;
Q: population estimate for intercompartmental clearance; Vp: population estimate of apparent volume of distribution in peripheral compartment; CL month 1 diff: population
estimate difference in clearance of first month; IIV: inter-individual variability; IOV: inter-occasion variability. 
centrations, hence presumably characterized by a lower
clearance. Calculations based on the total population
would, therefore, over-predict the clearance in this group,
resulting in the under-prediction of the Erwinia asparagi-
nase concentrations. When the predictions are corrected
for the dose interval, the under-prediction disappears and
is in accordance with the observations (Online
Supplementary Figure S1).   
Monte Carlo simulations of patients with different body
weights and starting doses of Erwinia asparaginase were
performed aiming at trough concentrations of 100 IU/L or
more. Based on the simulations, the current starting dose
of 20,000 IU/m2 seems rather low, especially for children
with a body weight less than 50 kg. If this starting dose is
used, close monitoring of the patient is required to ensure
sufficient Erwinia asparaginase concentrations. The PK
model uses the standard allometric scaling based on
weight, which is the gold standard for allometric scaling in
population PK. Unlike weight-based scaling, it is unclear
how scaling based on BSA should be implemented. The
implementation of BSA in the PK model might depend on
the chosen method of BSA calculation (e.g. Mosteller,
Dubois & Dubois, Haycock), as these methods use differ-
ent internal (exponential) correction factors.35-37 However,
to our knowledge, this has still not been studied.
Therefore, weight-based allometric scaling was used for
the development of the PK model. Monte Carlo simula-
tions were also expressed on a per weight basis.
Additional simulations were performed with scaling based
on BSA resulting in similar results. For clinical conven-
ience, the dose was converted to IU/m2 using the corre-
sponding BSA to weight in pediatric oncology patients for
the representation of Figures 5B and 6B.30 With the regis-
tered dose of 25,000 IU/m2, approximately 75% of the
patients have Erwinia asparaginase concentrations above
100 IU/L 48 h after the first dose and 90%-100% of the
patients above 50 IU/L.
When increasing the dose to achieve sufficient trough
concentrations, one has to keep in mind that the peak con-
centrations (Cmax) and exposure (AUC) increase as well.
This might lead to side effects which include hypersensi-
tivity or infusion reactions, pancreatitis, liver abnormali-
ties, central neurotoxicities, glucose intolerance or coagu-
lation abnormalities,24,38,39 although we showed no signifi-
cant correlation between asparaginase activity concentra-
tions and pancreatitis, thrombosis or central neurotoxici-
ties.39 High concentrations of asparaginase were associated
with high triglyceride and high cholesterol concentrations,
and were more pronounced in children aged ten years or
older. This might be explained by the lower weight nor-
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Figure 4. Simulated Erwinia asparaginase concentra-
tions for a 10 kg and a 100 kg patient.  Median and
the 25% and 75% percentiles of the patients who
achieve asparaginase concentrations (y-axis) after 48
hours for different Erwinia asparaginase doses (x-
axis). (A) Concentrations for a 10 kg patient and (B) a
100 kg patient. Red dashed line is the target trough
concentration of 100 IU/L.
A
B
malized clearance in older children.39 Information concern-
ing specific toxic concentrations was not available there-
fore maximum concentrations (Cmax) and exposure (area
under the curve) were not evaluated. In addition, due to
the increased clearance in the first month, the plasma con-
centrations will be lower compared to the following
months. Hence increasing the dose might not be neces-
sary. 
A potential limitation of this study was that samples
were collected during the TDM procedure and predomi-
nantly withdrawn at 48 and 72 h after administration.
Additional peak samples were collected during the first
hours after administration. Patients were at home in the
period between the peak (first hours after dose) and
trough concentrations (prior to the next dose), therefore
Erwinia asparaginase concentrations within this time-
frame were not available. However, with Erwinia asparag-
inase dosing, the aim is to achieve sufficient trough con-
centrations to assure complete asparagine depletion prior
to the next dose (which is after 48 or 72 h), and the dose
will be adjusted according to those time points. Two
patients were excluded from the analysis due to non-mea-
surable asparaginase levels. One patient had antibodies,
which could explain the lack of asparaginase; the other
patient might have had a very fast asparaginase clearance.
Excluding these patients could result in a lower variability
and estimated clearance. 
With the registered Erwinia asparaginase dose of 25,000
IU/m2, approximately 25% of the patients will not have 48
h trough concentrations above 100 IU/L after their first
dose. This will be more pronounced in those patients with
a low body weight. However, the PK analysis showed an
increased clearance in the first month, therefore Erwinia
asparaginase concentrations will increase after the first
month. Monitoring the plasma concentrations and adjust-
ing the dose for the individual patients presented with
concentrations below target threshold is recommended.
Asparagine is completely depleted with Erwinia asparagi-
nase concentrations of 100 IU/L or more, although some
studies show complete depletion at lower concentra-
tions.7,9,13,15,16,40 Increasing the dose for the group as a whole
might lead to unnecessarily high concentrations in the
majority of the patients with concentrations already over
100 IU/L, hence resulting in possible (long-term) side
effects and unnecessary costs. Therefore, individual dose
adjustments are recommended. 
The optimal treatment would be dose adjustments
based on patients’ individual PK parameters. With the PK
model developed in this study, the individualized dose
requirements can be calculated via post-hoc Bayesian analy-
sis. This might reduce possible under-exposure that could
potentially result in relapse, as well as reduce high concen-
trations. A prospective randomized controlled trial could
compare conventional dosing versus individualized PK-
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Figure 5. Erwinia asparaginase starting dose versus
patient weight to achieve 100 IU/L or more after 48
hours (h). (A) Required starting dose in IU/kg and (B)
IU/m2 versus weight of patients in kilograms (kg) to
achieve 100 IU/L or more after 48 h. Median (solid
line), 25% and 75% percentiles (dashed line) and
10% and 90% percentiles (dotted line) of the patients
with asparaginase concentrations of 100 IU/L or
more with different weight (x-axis) and different start-
ing doses (y-axis).
A
B
based Erwinia asparaginase dosing to evaluate whether
individual Erwinia asparaginase concentrations would
improve and whether this affects treatment outcome.
However, due to the limited number of Erwinia asparagi-
nase-treated patients in the Netherlands, this is not possi-
ble and should be performed on an international level. A
rational approach should be adopted for dose manage-
ment to ensure adequate trough concentrations. 
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